How should you assess the fair value of FPH (Fisher & Paykel Healthcare Corp)?

We do not publish a fair value estimate for FPH, because any single number would hide the assumptions doing all the work — growth rate, margin path and discount rate. Change any one of those modestly and the output moves enormously.

What our data shows is the market's current answer: FPH last traded at 42.50.

Its 52-week range is 32.16 – 43.19, placing the current price about 93.7% of the way up that range.

Three checks are more useful than a target price: how the current multiple compares with the company's own history, whether recent earnings growth actually supports it, and how much of the story depends on a single product or customer.

As a Healthcare company, FPH will also be re-rated by whatever is repricing that whole sector, independently of company performance.

Nothing here is investment advice or a recommendation to buy or sell.

A practical addition: most investors reading this own FPH indirectly through funds rather than directly. If that is you, the valuation question is less useful than the exposure question — how much of your portfolio is already in this one company.

We are not licensed to advise on individual securities, and nothing here is a recommendation.